Comprehensive Analysis Reveals the Potential Roles of CDKN3 in Pancancer and Verification in Endometrial Cancer

References

• Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. doi:10.3322/caac.21763
   PubMed Web of Science ®Google Scholar
• Wei W, Zeng H, Zheng R, et al. Cancer registration in China and its role in cancer prevention and control. Lancet Oncol. 2020;21(7):e342–e349. doi:10.1016/s1470-2045(20)30073-5
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Cress WD, Yu P, Wu J. Expression and alternative splicing of the cyclin-dependent kinase inhibitor-3 gene in human cancer. Int J Biochem Cell Biol. 2017;91(Pt B):98–101. doi:10.1016/j.biocel.2017.05.013
   PubMedGoogle Scholar
• Malumbres M. Cyclin-dependent kinases. Genome Biol. 2014;15(6):122. doi:10.1186/gb4184
   PubMed Web of Science ®Google Scholar
• Yu Y, Jiang X, Schoch BS, Carroll RS, Black PM, Johnson MD. Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma. Cancer Res. 2007;67(1):130–138. doi:10.1158/0008-5472.Can-06-2478
   PubMed Web of Science ®Google Scholar
• Li WH, Zhang L, Wu YH. CDKN3 regulates cisplatin resistance to colorectal cancer through TIPE1. Eur Rev Med Pharmacol Sci Apr. 2020;24(7):3614–3623. doi:10.26355/eurrev_202004_20823
   PubMed Web of Science ®Google Scholar
• Barrón EV, Roman-Bassaure E, Sánchez-Sandoval AL, et al. CDKN3 mRNA as a biomarker for survival and therapeutic target in cervical cancer. PLoS One. 2015;10(9):e0137397. doi:10.1371/journal.pone.0137397
   PubMed Web of Science ®Google Scholar
• Liu D, Zhang J, Wu Y, et al. YY1 suppresses proliferation and migration of pancreatic ductal adenocarcinoma by regulating the CDKN3/MdM2/P53/P21 signaling pathway. Int J Cancer. 2018;142(7):1392–1404. doi:10.1002/ijc.31173
   PubMed Web of Science ®Google Scholar
• Li Y, Ji S, Fu LY, Jiang T, Wu D, Meng FD. Knockdown of cyclin-dependent kinase inhibitor 3 inhibits proliferation and invasion in human gastric cancer cells. Oncol Res. 2017;25(5):721–731. doi:10.3727/096504016x14772375848616
   PubMed Web of Science ®Google Scholar
• Liu J, Min L, Zhu S, et al. Cyclin-dependent kinase inhibitor 3 promoted cell proliferation by driving cell cycle from G1 to S phase in esophageal squamous cell carcinoma. J Cancer. 2019;10(8):1915–1922. doi:10.7150/jca.27053
   PubMed Web of Science ®Google Scholar
• Wang H, Chen H, Zhou H, Yu W, Lu Z. Cyclin-dependent kinase inhibitor 3 promotes cancer cell proliferation and tumorigenesis in nasopharyngeal carcinoma by targeting p27. Oncol Res. 2017;25(9):1431–1440. doi:10.3727/096504017x14835311718295
   PubMed Web of Science ®Google Scholar
• Pan XW, Zhang H, Xu D, et al. Identification of a novel cancer stem cell subpopulation that promotes progression of human fatal renal cell carcinoma by single-cell RNA-seq analysis. Int J Biol Sci. 2020;16(16):3149–3162. doi:10.7150/ijbs.46645
   PubMed Web of Science ®Google Scholar
• Srinivas V, Kitagawa M, Wong J, Liao PJ, Lee SH. The tumor suppressor Cdkn3 is required for maintaining the proper number of centrosomes by regulating the centrosomal stability of Mps1. Cell Rep. 2015;13(8):1569–1577. doi:10.1016/j.celrep.2015.10.039
   PubMed Web of Science ®Google Scholar
• Nalepa G, Barnholtz-Sloan J, Enzor R, et al. The tumor suppressor CDKN3 controls mitosis. J Cell Biol. 2013;201(7):997–1012. doi:10.1083/jcb.201205125
   PubMed Web of Science ®Google Scholar
• Abdel-Tawab MS, Fouad H, Othman AM, et al. Evaluation of gene expression of PLEKHS1, AADAC, and CDKN3 as novel genomic markers in gastric carcinoma. PLoS One. 2022;17(4):e0265184. doi:10.1371/journal.pone.0265184
   PubMed Web of Science ®Google Scholar
• Chen Q, Chen K, Guo G, et al. A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis. PLoS One. 2014;9(10):e111611. doi:10.1371/journal.pone.0111611
   PubMed Web of Science ®Google Scholar
• Dai W, Miao H, Fang S, Fang T, Chen N, Li M. CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma. Mol Med Rep. 2016;14(2):1509–1514. doi:10.3892/mmr.2016.5410
   PubMed Web of Science ®Google Scholar
• Zhang LP, Li WJ, Zhu YF, et al. CDKN3 knockdown reduces cell proliferation, invasion and promotes apoptosis in human ovarian cancer. Int J Clin Exp Pathol. 2015;8(5):4535–4544.
   PubMed Web of Science ®Google Scholar
• Deng M, Wang J, Chen Y, et al. Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines. Mol Med Rep. 2016;14(2):1523–1530. doi:10.3892/mmr.2016.5401
   PubMed Web of Science ®Google Scholar
• da Silva Maués JH, Ferreira Ribeiro H, De maria maués sacramento R, et al. Downregulated genes by silencing MYC pathway identified with RNA-SEQ analysis as potential prognostic biomarkers in gastric adenocarcinoma. Aging. 2020;12(24):24651–24670. doi:10.18632/aging.202260
   PubMedGoogle Scholar
• Fan C, Chen L, Huang Q, et al. Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma. Br J Cancer. 2015;113(12):1735–1743. doi:10.1038/bjc.2015.378
   PubMed Web of Science ®Google Scholar
• Xu WH, Wu J, Wang J, et al. Screening and identification of potential prognostic biomarkers in adrenocortical carcinoma. Front Genet. 2019;10:821. doi:10.3389/fgene.2019.00821
   PubMed Web of Science ®Google Scholar
• Mori J, Sawada T, Baba T, et al. Identification of cell cycle-associated and -unassociated regulators for expression of a hepatocellular carcinoma oncogene cyclin-dependent kinase inhibitor 3. Biochem Biophys Res Commun. 2022;625:46–52. doi:10.1016/j.bbrc.2022.07.088
   PubMed Web of Science ®Google Scholar
• Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412–1428. doi:10.1016/s0140-6736(22)00323-3
   PubMed Web of Science ®Google Scholar
• Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6(10):813–823. doi:10.1038/nrc1951
   PubMed Web of Science ®Google Scholar
• Klutstein M, Nejman D, Greenfield R, Cedar H. DNA methylation in cancer and aging. Cancer Res. 2016;76(12):3446–3450. doi:10.1158/0008-5472.Can-15-3278
   PubMed Web of Science ®Google Scholar
• Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38(1):23–38. doi:10.1038/npp.2012.112
   PubMed Web of Science ®Google Scholar
• Niculescu MD, Craciunescu CN, Zeisel SH. Dietary choline deficiency alters global and gene-specific DNA methylation in the developing hippocampus of mouse fetal brains. FASEB J. 2006;20(1):43–49. doi:10.1096/fj.05-4707com
   PubMed Web of Science ®Google Scholar
• Long ZJ, Wang JD, Xu JQ, Lei XX, Liu Q. cGAS/STING cross-talks with cell cycle and potentiates cancer immunotherapy. Mol Ther. 2022;30(3):1006–1017. doi:10.1016/j.ymthe.2022.01.044
   PubMed Web of Science ®Google Scholar
• Zhang W, Liu W, Jia L, et al. Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress. Mol Cell. 2021;81(10):2148–2169. doi:10.1016/j.molcel.2021.02.038
   PubMed Web of Science ®Google Scholar
• Wang J, Che W, Wang W, Su G, Zhen T, Jiang Z. CDKN3 promotes tumor progression and confers cisplatin resistance via RAD51 in esophageal cancer. Cancer Manag Res. 2019;11:3253–3264. doi:10.2147/cmar.S193793
   PubMed Web of Science ®Google Scholar
• Li M, Che N, Jin Y, Li J, Yang W. CDKN3 overcomes bladder cancer cisplatin resistance via LDHA-dependent glycolysis reprogramming. Onco Targets Ther. 2022;15:299–311. doi:10.2147/ott.S358008
   PubMed Web of Science ®Google Scholar
• Lee SW, Reimer CL, Fang L, Iruela-Arispe ML, Aaronson SA. Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression. Mol Cell Biol. 2000;20(5):1723–1732. doi:10.1128/mcb.20.5.1723-1732.2000
   PubMed Web of Science ®Google Scholar
• Gyuris J, Golemis E, Chertkov H, Brent R. Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. Cell. 1993;75(4):791–803. doi:10.1016/0092-8674(93)90498-f
   PubMed Web of Science ®Google Scholar
• Song H, Hanlon N, Brown NR, Noble ME, Johnson LN, Barford D. Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phosphoCDK2. Mol Cell. 2001;7(3):615–626. doi:10.1016/s1097-2765(01)00208-8
   PubMed Web of Science ®Google Scholar
• Lolli G, Lowe ED, Brown NR, Johnson LN. The crystal structure of human CDK7 and its protein recognition properties. Structure. 2004;12(11):2067–2079. doi:10.1016/j.str.2004.08.013
   PubMed Web of Science ®Google Scholar
• Hannon GJ, Casso D, Beach D. KAP: a dual specificity phosphatase that interacts with cyclin-dependent kinases. Proc Natl Acad Sci U S A. 1994;91(5):1731–1735. doi:10.1073/pnas.91.5.1731
   PubMed Web of Science ®Google Scholar
• Poon RY, Hunter T. Dephosphorylation of Cdk2 Thr 160 by the cyclin-dependent kinase-interacting phosphatase KAP in the absence of cyclin. Science. 1995;270(5233):90. doi:10.1126/science.270.5233.90
   PubMed Web of Science ®Google Scholar
• Fauman EB, Saper MA. Structure and function of the protein tyrosine phosphatases. Trends Biochem Sci. 1996;21(11):413–417. doi:10.1016/s0968-0004(96)10059-1
   PubMed Web of Science ®Google Scholar
• Poon RY. Generation of phosphorylated cyclin-dependent kinase 2 and functional characterization of threonine-160-specific phosphatase KAP. Methods Enzymol. 1997;283:283–292. doi:10.1016/s0076-6879(97)83023-6
   PubMed Web of Science ®Google Scholar
• Brown NR, Noble ME, Lawrie AM, et al. Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J Biol Chem. 1999;274(13):8746–8756. doi:10.1074/jbc.274.13.8746
   PubMed Web of Science ®Google Scholar
• Barford D. The mechanism of protein kinase regulation by protein phosphatases. Biochem Soc Trans. 2001;29(10):2148–2165.e9. doi:10.1016/j.molcel.2021.02.038
   Google Scholar
• Yeh CT, Lu SC, Chao CH, Chao ML. Abolishment of the interaction between cyclin-dependent kinase 2 and Cdk-associated protein phosphatase by a truncated KAP mutant. Biochem Biophys Res Commun. 2003;305(2):311–314. doi:10.1016/s0006-291x(03)00757-5
   PubMed Web of Science ®Google Scholar
• Chinami M, Yano Y, Yang X, et al. Binding of HTm4 to Cyclin-dependent Kinase (Cdk)-associated Phosphatase (KAP)·Cdk2·Cyclin A complex enhances the phosphatase activity of KAP, dissociates Cyclin A, and facilitates KAP Dephosphorylation of Cdk2. J Biol Chem. 2005;280(17):1731–1735. doi:10.1073/pnas.91.5.1731
   Web of Science ®Google Scholar
• Espinosa AM, Alfaro A, Roman-Basaure E, et al. Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer. PLoS One. 2013;8(2):e55975. doi:10.1371/journal.pone.0055975
   PubMed Web of Science ®Google Scholar
• Yu C, Cao H, He X, et al. Cyclin-dependent kinase inhibitor 3 (CDKN3) plays a critical role in prostate cancer via regulating cell cycle and DNA replication signaling. Biomed Pharmacother. 2017;96:1109–1118. doi:10.1016/j.biopha.2017.11.112
   PubMed Web of Science ®Google Scholar
• Xing C, Xie H, Zhou L, et al. Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation. Biochem Biophys Res Commun. 2012;420(1):29–35. doi:10.1016/j.bbrc.2012.02.107
   PubMed Web of Science ®Google Scholar
• Yu H, Yao J, Du M, Ye J, He X, Yin L. CDKN3 promotes cell proliferation, invasion and migration by activating the AKT signaling pathway in esophageal squamous cell carcinoma. Oncol Lett. 2020;19(1):542–548. doi:10.3892/ol.2019.11077
   PubMed Web of Science ®Google Scholar
• Jiang Y, Lyu T, Che X, Jia N, Li Q, Feng W. Overexpression of SMYD3 in ovarian cancer is associated with ovarian cancer proliferation and apoptosis via methylating H3K4 and H4K20. J Cancer. 2019;10(17):4072–4084. doi:10.7150/jca.29861
   PubMed Web of Science ®Google Scholar
• Li X, Ni M, Xiong W, et al. Transcriptomics analysis and benchmark concentration estimating-based in vitro test with IOSE80 cells to unveil the mode of action for female reproductive toxicity of bisphenol A at human-relevant levels. Ecotoxicol Environ Saf. 2022;237:113523. doi:10.1016/j.ecoenv.2022.113523
   PubMed Web of Science ®Google Scholar
• Lee J, Sung CO, Lee EJ, et al. Metastasis of neuroendocrine tumors are characterized by increased cell proliferation and reduced expression of the ATM gene. PLoS One. 2012;7(4):e34456. doi:10.1371/journal.pone.0034456
   PubMed Web of Science ®Google Scholar
• Baldi A, Piccolo MT, Boccellino MR, et al. Apoptosis induced by piroxicam plus cisplatin combined treatment is triggered by p21 in mesothelioma. PLoS One. 2011;6(8):e23569. doi:10.1371/journal.pone.0023569
   PubMed Web of Science ®Google Scholar
• Li Y, Yang Q, Guan H, Shi B, Ji M, Hou P. ZNF677 suppresses Akt phosphorylation and tumorigenesis in thyroid cancer. Cancer Res. 2018;78(18):5216–5228. doi:10.1158/0008-5472.Can-18-0003
   PubMed Web of Science ®Google Scholar
• Islam MA, Hossen MB, Horaira MA, et al. Exploring core genes by comparative transcriptomics analysis for early diagnosis, prognosis, and therapies of colorectal cancer. Cancers (Basel). 2023;15(5):1369. doi:10.3390/cancers15051369
   PubMed Web of Science ®Google Scholar
• Yang C, Wei Y, Li W, et al. Prognostic risk signature and comprehensive analyses of endoplasmic reticulum stress-related genes in lung adenocarcinoma. J Immunol Res. 2022;2022:6567916. doi:10.1155/2022/6567916
   PubMed Web of Science ®Google Scholar
• Yang B, Luo L, Luo W, et al. The genomic dynamics during progression of lung adenocarcinomas. J Hum Genet. 2017;62(8):783–788. doi:10.1038/jhg.2017.40
   PubMed Web of Science ®Google Scholar
• Qi L, Zhou B, Chen J, et al. Significant prognostic values of differentially expressed-aberrantly methylated hub genes in breast cancer. J Cancer. 2019;10(26):6618–6634. doi:10.7150/jca.33433
   PubMed Web of Science ®Google Scholar
• Sang L, Wang XM, Xu DY, Zhao WJ. Bioinformatics analysis of aberrantly methylated-differentially expressed genes and pathways in hepatocellular carcinoma. World J Gastroenterol. 2018;24(24):2605–2616. doi:10.3748/wjg.v24.i24.2605
   PubMed Web of Science ®Google Scholar
• Li Y, Wei Z, Huang S, Yang B. mRNA expression and DNA methylation analysis of the inhibitory mechanism of H(2)O(2) on the proliferation of A549 cells. Oncol Lett. 2020;20(6):288. doi:10.3892/ol.2020.12151
   PubMed Web of Science ®Google Scholar
• Niculescu MD, Yamamuro Y, Zeisel SH. Choline availability modulates human neuroblastoma cell proliferation and alters the methylation of the promoter region of the cyclin-dependent kinase inhibitor 3 gene. J Neurochem. 2004;89(5):1252–1259. doi:10.1111/j.1471-4159.2004.02414.x
   PubMed Web of Science ®Google Scholar
• Ma Z, Liu Y, Hao Z, Hua X, Li W. DNA hypermethylation of Aurora kinase A in hepatitis C virus-positive hepatocellular carcinoma. Mol Med Rep. 2019;20(3):2519–2532. doi:10.3892/mmr.2019.10487
   PubMed Web of Science ®Google Scholar
• Yaqinuddin A, Qureshi SA, Qazi R, Abbas F. Down-regulation of DNMT3b in PC3 cells effects locus-specific DNA methylation, and represses cellular growth and migration. Cancer Cell Int. 2008;8(1):13. doi:10.1186/1475-2867-8-13
   PubMedGoogle Scholar
• Nowosad A, Jeannot P, Callot C, et al. p27 controls Ragulator and mTOR activity in amino acid-deprived cells to regulate the autophagy-lysosomal pathway and coordinate cell cycle and cell growth. Nat Cell Biol. 2020;22(9):1076–1090. doi:10.1038/s41556-020-0554-4
   PubMed Web of Science ®Google Scholar
• Yang C, Chen L, Niu Q, et al. Identification and validation of an E2F-related gene signature for predicting recurrence-free survival in human prostate cancer. Cancer Cell Int. 2022;22(1):382. doi:10.1186/s12935-022-02791-9
   PubMed Web of Science ®Google Scholar
• Li S, Xue P, Diao X, et al. Identification and validation of functional roles for three MYC-associated genes in hepatocellular carcinoma. J Adv Res. 2023;54:133–146. doi:10.1016/j.jare.2023.01.010
   PubMed Web of Science ®Google Scholar
• Miao Y, Cui L, Chen Z, Zhang L. Gene expression profiling of DMU-212-induced apoptosis and anti-angiogenesis in vascular endothelial cells. Pharm Biol. 2016;54(4):660–666. doi:10.3109/13880209.2015.1071414
   PubMed Web of Science ®Google Scholar
• Tang B, Hu L, Jiang T, et al. A metabolism-related gene prognostic index for prediction of response to immunotherapy in lung adenocarcinoma. Int J Mol Sci. 2022;23(20):12143. doi:10.3390/ijms232012143
   PubMed Web of Science ®Google Scholar
• Yang Y, Deng X, Chen X, et al. Landscape of active enhancers developed de novo in cirrhosis and conserved in hepatocellular carcinoma. Am J Cancer Res. 2020;10(10):3157–3178.
   PubMed Web of Science ®Google Scholar
• Yao S, Deng M, Du X, Huang R, Chen Q. A novel hypoxia related marker in blood link to aid diagnosis and therapy in osteoarthritis. Genes. 2022;13(9):1501. doi:10.3390/genes13091501
   PubMed Web of Science ®Google Scholar
• Qian XF, Zhang JH, Mai YX, et al. A novel insight into paraptosis-related classification and signature in lower-grade gliomas. Int J Genomics. 2022;2022:6465760. doi:10.1155/2022/6465760
   PubMed Web of Science ®Google Scholar
• Simpson NE, Tryndyak VP, Pogribna M, Beland FA, Pogribny IP. Modifying metabolically sensitive histone marks by inhibiting glutamine metabolism affects gene expression and alters cancer cell phenotype. Epigenetics. 2012;7(12):1413–1420. doi:10.4161/epi.22713
   PubMed Web of Science ®Google Scholar
• Turpaev K, Glatigny A, Bignon J, Delacroix H, Drapier JC. Variation in gene expression profiles of human monocytic U937 cells exposed to various fluxes of nitric oxide. Free Radic Biol Med. 2010;48(2):298–305. doi:10.1016/j.freeradbiomed.2009.10.054
   PubMed Web of Science ®Google Scholar
• Donato JL, Ko J, Kutok JL, et al. Human HTm4 is a hematopoietic cell cycle regulator. J Clin Invest. 2002;109(1):51–58. doi:10.1172/jci14025
   PubMed Web of Science ®Google Scholar
• Iriuchijima N, Sato-Harada R, Takano M, et al. Reduced expression of kinase-associated phosphatase in cortical dendrites of MAP2-deficient mice. Biochem Biophys Res Commun. 2005;338(2):1216–1221. doi:10.1016/j.bbrc.2005.10.077
   PubMed Web of Science ®Google Scholar
• Ozawa S, Gamou T, Habano W, et al. Altered expression of GADD45 genes during the development of chemical-mediated liver hypertrophy and liver tumor promotion in rats. J Toxicol Sci. 2011;36(5):613–623. doi:10.2131/jts.36.613
   PubMed Web of Science ®Google Scholar
• Alvarez MS, Fernandez-Alvarez A, Cucarella C, Casado M. Stable SREBP-1a knockdown decreases the cell proliferation rate in human preadipocyte cells without inducing senescence. Biochem Biophys Res Commun. 2014;447(1):51–56. doi:10.1016/j.bbrc.2014.03.104
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang X, Yao J, Qiu Z. Long non-coding RNA NEAT1 inhibits oxidative stress-induced vascular endothelial cell injury by activating the miR-181d-5p/CDKN3 axis. Artif Cells Nanomed Biotechnol. 2019;47(1):3129–3137. doi:10.1080/21691401.2019.1646264
   PubMed Web of Science ®Google Scholar
• Pabla S, Conroy JM, Nesline MK, et al. Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. J Immunother Cancer. 2019;7(1):27. doi:10.1186/s40425-019-0506-3
   PubMed Web of Science ®Google Scholar
• Chen CF, Feng X, Liao HY, et al. Regulation of T cell proliferation by JMJD6 and PDGF-BB during chronic hepatitis B infection. Sci Rep. 2014;4(1):6359. doi:10.1038/srep06359
   PubMedGoogle Scholar
• Chen Y, Chen Z, Mo J, et al. Identification of HCG18 and MCM3AP-AS1 that associate with bone metastasis, poor prognosis and increased abundance of M2 macrophage infiltration in prostate cancer. Technol Cancer Res Treat. 2021;20:1533033821990064. doi:10.1177/1533033821990064
   Web of Science ®Google Scholar
• Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24(1):26. doi:10.1186/s12929-017-0329-9
   PubMedGoogle Scholar
• Deng Y, Song Z, Huang L, et al. Tumor purity as a prognosis and immunotherapy relevant feature in cervical cancer. Aging. 2021;13(22):24768–24785. doi:10.18632/aging.203714
   PubMedGoogle Scholar
• Jiang S, Ding X, Wu Q, Cheng T, Xu M, Huang J. Identifying immune cells-related phenotype to predict immunotherapy and clinical outcome in gastric cancer. Front Immunol. 2022;13:980986. doi:10.3389/fimmu.2022.980986
   PubMed Web of Science ®Google Scholar
• Korbecki J, Kojder K, Kapczuk P, et al. The effect of hypoxia on the expression of CXC chemokines and CXC chemokine receptors-A review of literature. Int J Mol Sci. 2021;22(2):843. doi:10.3390/ijms22020843
   PubMed Web of Science ®Google Scholar
• Chang TT, Chen C, Chen JW. CCL7 as a novel inflammatory mediator in cardiovascular disease, diabetes mellitus, and kidney disease. Cardiovasc Diabetol. 2022;21(1):185. doi:10.1186/s12933-022-01626-1
   PubMed Web of Science ®Google Scholar
• Dangi A, Husain I, Jordan CZ, et al. Blocking CCL8-CCR8-mediated early allograft inflammation improves kidney transplant function. J Am Soc Nephrol. 2022;33(10):1876–1890. doi:10.1681/asn.2022020139
   PubMed Web of Science ®Google Scholar
• Korbecki J, Kojder K, Simińska D, et al. CC chemokines in a tumor: a review of pro-cancer and anti-cancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4. Int J Mol Sci. 2020;21(21):7619.
   PubMed Web of Science ®Google Scholar
• Dostert C, Grusdat M, Letellier E, Brenner D. The TNF family of ligands and receptors: communication modules in the immune system and beyond. Physiol Rev. 2019;99(1):115–160. doi:10.1152/physrev.00045.2017
   PubMed Web of Science ®Google Scholar
• Cekanova M, Yuan JS, Li X, Kim K, Baek SJ. Gene alterations by peroxisome proliferator-activated receptor gamma agonists in human colorectal cancer cells. Int J Oncol. 2008;32(4):809–819.
   PubMed Web of Science ®Google Scholar
• Mohr T, Katz S, Paulitschke V, Aizarani N, Tolios A. Systematic analysis of the transcriptome profiles and co-expression networks of tumour endothelial cells identifies several tumour-associated modules and potential therapeutic targets in hepatocellular carcinoma. Cancers. 2021;13(8). doi:10.3390/cancers1308176
   Web of Science ®Google Scholar
• Khaleghi S, Aziz AA, Razali N, Junit SM. Microarray analysis revealed different gene expression patterns in HepG2 cells treated with low and high concentrations of the extracts of Anacardium occidentale shoots. Genes Nutr. 2011;6(4):413–427. doi:10.1007/s12263-011-0216-z
   PubMed Web of Science ®Google Scholar
• Chen Q, Wang L, Wu H, et al. Specific blood RNA profiles in individuals with acute spinal cord injury as compared with trauma controls. Oxid Med Cell Longev. 2023;2023:1485135. doi:10.1155/2023/1485135
   PubMed Web of Science ®Google Scholar
• Şiğva Z D, Balci Okcanoğlu T, Avci Ç B, et al. Investigation of the synergistic effects of paclitaxel and herbal substances and endemic plant extracts on cell cycle and apoptosis signal pathways in prostate cancer cell lines. Gene. 2019;687:261–271. doi:10.1016/j.gene.2018.11.049
   PubMed Web of Science ®Google Scholar
• Alkhezayem S, Wani TA, Wakil S, Aljuraysi A, Zargar S. Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib. Saudi Pharm J. 2020;28(8):963–970. doi:10.1016/j.jsps.2020.06.017
   PubMed Web of Science ®Google Scholar
• Chen H, Wu J, Lu L, et al. Identification of hub genes associated with immune infiltration and predict prognosis in hepatocellular carcinoma via bioinformatics approaches. Front Genet. 2021;11:575762. doi:10.3389/fgene.2020.575762
   PubMed Web of Science ®Google Scholar